FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154928863> ?p ?o ?g. }

• W3154928863 endingPage "69" @default.
• W3154928863 startingPage "61" @default.
• W3154928863 abstract "Aim. Assessment of the efficacy and adherence to treatment with acetylsalicylic acid (ASA) and clopidogrel combination drug compared to separate administration of the drugs in patients with acute coronary syndrome and patients with chronic coronary syndrome after coronary stent implantation. Materials and methods. The study included 100 patients randomized to receive either original clopidogrel (Plavix® Sanofi) only or original ASA (Aspirin® Cardio Bayer) only or the generic fixed drug combination (Plagril® A Dr. Reddy's Laboratories Ltd.). Over the first 7–10 days after the index event, all patients were treated with a separate drug in the hospital, then received double antiplatelet therapy with appropriate drugs on an outpatient basis for 4 months, and purchased the drugs on their own for the last 2 months of follow-up. Monitoring the efficacy of therapy and patient adherence to treatment was carried out according to the clinic data, platelet aggregation indicators and blood thromboxane B2 (TXB2), salicylic acid and clopidogrel metabolite (carboxylic acid) levels on the 7th day after disease onset and after 8 and 16 weeks of treatment. Results. Most of the patients were elderly (mean age 68.3±10.6 years), of them 35% were women. After 8 and 16 weeks of treatment in hospital, platelet aggregation indicators did not differ between patients taking separate drugs or a fixed combination. The generic Plagril® A inhibited the aggregation response similarly to the original drugs. At moment of randomization, baseline blood TXB2, salicylic acid and the carboxyl metabolite of clopidogrel levels were comparable in both groups of patients (p>0.05). After 8 weeks of therapy, patients taking Plagril® A had significantly lower TXB2 levels compared with the separate administration of Plavix and Aspirin Cardio: 0.1±0.05 ng/ml vs 0.2±0.23 ng/ml, respectively (p<0.001). After 16 weeks, TXB2 levels reached 0.28±0.56 ng/ml vs 0.43±0.48 ng/ml, respectively (p=0.006). There were no differences in blood salicylic acid and clopidogrel carboxyl metabolite blood levels between the groups of patients during the entire study period. Adherence to antiplatelet therapy during inpatient period of treatment was 100%. In the first 8 weeks, it decreased to 74.5%, and after 16 weeks – to 71.5%. When taking the drugs separately, missing rate was higher in ASA group: 21.2% vs 5% in clopidogrel group. Conclusion. Plagril® A is bioequivalent and as effective as the original ASA and clopidogrel taken separately, in terms of the effect on platelet activity and blood clopidogrel metabolite levels. The adherence to a fixed combination of clopidogrel and ASA in patients with acute coronary syndrome and patients with chronic coronary syndrome is significantly higher than when these drugs are taken separately, both at the stages of free treatment and when purchasing drugs on their own. Keywords: antiplatelet therapy, acetylsalicylic acid, clopidogrel, adherence to secondary prevention, coronary heart disease For citation: Lomakin NV, Buryachkovskaya LI, Senichkina AA, Sumarokov AB, Docenko UV, Kazey VI. Use of combination pills with acetylsalicylic acid and clopidogrel in coronary artery disease. Efficacy and assessment of adherence to treatment: Kobra Study. Consilium Medicum. 2021; 23 (1): 61–69. DOI: 10.26442/20751753.2021.1.200780" @default.
• W3154928863 created "2021-04-26" @default.
• W3154928863 creator A5035748197 @default.
• W3154928863 creator A5039816494 @default.
• W3154928863 creator A5042428465 @default.
• W3154928863 creator A5045880367 @default.
• W3154928863 creator A5059394775 @default.
• W3154928863 creator A5076163733 @default.
• W3154928863 date "2021-01-01" @default.
• W3154928863 modified "2023-10-14" @default.
• W3154928863 title "Use of combination pills with acetylsalicylic acid and clopidogrel in coronary artery disease. Efficacy and assessment of adherence to treatment: Kobra Study" @default.
• W3154928863 doi "https://doi.org/10.26442/20751753.2021.1.200780" @default.
• W3154928863 hasPublicationYear "2021" @default.
• W3154928863 type Work @default.
• W3154928863 sameAs 3154928863 @default.
• W3154928863 citedByCount "0" @default.
• W3154928863 crossrefType "journal-article" @default.
• W3154928863 hasAuthorship W3154928863A5035748197 @default.
• W3154928863 hasAuthorship W3154928863A5039816494 @default.
• W3154928863 hasAuthorship W3154928863A5042428465 @default.
• W3154928863 hasAuthorship W3154928863A5045880367 @default.
• W3154928863 hasAuthorship W3154928863A5059394775 @default.
• W3154928863 hasAuthorship W3154928863A5076163733 @default.
• W3154928863 hasConcept C126322002 @default.
• W3154928863 hasConcept C149172746 @default.
• W3154928863 hasConcept C2776999253 @default.
• W3154928863 hasConcept C2777265216 @default.
• W3154928863 hasConcept C2777628954 @default.
• W3154928863 hasConcept C2777698277 @default.
• W3154928863 hasConcept C2777849778 @default.
• W3154928863 hasConcept C2778213512 @default.
• W3154928863 hasConcept C2780035454 @default.
• W3154928863 hasConcept C500558357 @default.
• W3154928863 hasConcept C71924100 @default.
• W3154928863 hasConcept C98274493 @default.
• W3154928863 hasConceptScore W3154928863C126322002 @default.
• W3154928863 hasConceptScore W3154928863C149172746 @default.
• W3154928863 hasConceptScore W3154928863C2776999253 @default.
• W3154928863 hasConceptScore W3154928863C2777265216 @default.
• W3154928863 hasConceptScore W3154928863C2777628954 @default.
• W3154928863 hasConceptScore W3154928863C2777698277 @default.
• W3154928863 hasConceptScore W3154928863C2777849778 @default.
• W3154928863 hasConceptScore W3154928863C2778213512 @default.
• W3154928863 hasConceptScore W3154928863C2780035454 @default.
• W3154928863 hasConceptScore W3154928863C500558357 @default.
• W3154928863 hasConceptScore W3154928863C71924100 @default.
• W3154928863 hasConceptScore W3154928863C98274493 @default.
• W3154928863 hasIssue "1" @default.
• W3154928863 hasLocation W31549288631 @default.
• W3154928863 hasOpenAccess W3154928863 @default.
• W3154928863 hasPrimaryLocation W31549288631 @default.
• W3154928863 hasRelatedWork W162222787 @default.
• W3154928863 hasRelatedWork W2120246543 @default.
• W3154928863 hasRelatedWork W2159355952 @default.
• W3154928863 hasRelatedWork W2161370825 @default.
• W3154928863 hasRelatedWork W2336402237 @default.
• W3154928863 hasRelatedWork W2358329200 @default.
• W3154928863 hasRelatedWork W2471991509 @default.
• W3154928863 hasRelatedWork W2889623858 @default.
• W3154928863 hasRelatedWork W3031290381 @default.
• W3154928863 hasRelatedWork W1889761305 @default.
• W3154928863 hasVolume "23" @default.
• W3154928863 isParatext "false" @default.
• W3154928863 isRetracted "false" @default.
• W3154928863 magId "3154928863" @default.
• W3154928863 workType "article" @default.